Reconstituted botulinum toxin type a does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use

Neurology

Volumn 48, Issue 1, 1997, Pages 249-253

  Sloop, R Richard ^a,b   Cole, Bradley A ^a   Escutin, Rodolfo O ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ANALYTIC METHOD; ARTICLE; DOSE RESPONSE; DRUG POTENCY; EXTENSOR DIGITORUM LONGUS MUSCLE; FREEZING; HUMAN; HUMAN EXPERIMENT; INTRAMUSCULAR DRUG ADMINISTRATION; NORMAL HUMAN; PARALYSIS; PRIORITY JOURNAL;

EID: 0031028416     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.1.249     Document Type: Article

References (20)

1. Jankovic J, Brin M. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-1194.
2. Schantz EJ, Kautter DA. Standardized assay for Clostridium botulinum toxins. J Assoc Off Anal Chem 1978;61:96-99.
3. Green P. Clinical trials for cervical dystonia 2. In: NIH consensus development conference on clinical use of botulinum toxin program. Bethesda, MD: NIH, November 1990:53-56.
4. Sloop RR, Escutin RO, Matus JA, Cole BA, Peterson GW. Dose response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum A toxin. Neurology 1996;46:1382-1386.
5. Gartlan MG, Hoffman HT. Crystalline preparation of botulinum toxin type A (BTX): degradation in potency with storage. Otolaryngol Head Neck Surg 1993;108:135-140.
6. Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 1993;8:479-483.
7. Mezaki T, Kaji R, Kohara N, et al. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology 1995;45:506-508.
8. Kauffman JA, Way JF, Siegel LS, Sellin LC. Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction. Toxicol Appl Pharmacol 1985;79:211-217.
9. Frueh BR, Felt DP, Wojno TH, Musch DC. Treatment of blepharospasm with botulinum toxin: a preliminary report. Arch Ophthalmol 1984;102:1464-1468.
10. Borodic GE, Cozzolino D. Blepharospasm and its treatment, with emphasis on the use of botulinum toxin. Plast Reconstr Surg 1989;83:546-554.
11. Sloop RR, Escutin RO, Cole BA. Human muscle paralysis from botulinum toxin injection: type A vs. type B [Abstract]. Neurology 1996;46(suppl 2):259.
12. Sellin LC, Thesleff S, Dasgupta BR. Different effect of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction. Acta Physiol Scand 1983;119:127-133.
13. Cull-Candy SG, Lundh H, Thesleff S. Effects of botulinum toxin on neuromuscular transmission in the rat. J Physiol 1976;260:177-203.
14. Shaari CM, Saunders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 1993;16:964-969.
15. Clarke CE. Therapeutic potential of botulinum toxin in neurological disorders. QJ Med 1992;299:197-205.
16. Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med 1993;86:493-494.
17. Pearce LB, Borodic GE, First ER, MacCallum RD. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 1994;128:69-77.
18. Pearce LB, Borodic GE, Johnson EA, First ER, MacCallum RD. The median paralysis unit: a more pharmacologically relevant unit of biological activity for botulinum toxin. Toxicon 1995;33:217-227.
19. Garcia A, Fulton JE. Cosmetic denervation of the muscles of facial expression with botulinum toxin: a dose-response study. Dermatol Surg 1996;22:39-43.
20. Greene P. Potency of frozen/thawed botulinum toxin type A in the treatment of torsion dystonia. Otolaryngol Head Neck Surg 1993;109:968-969.